Renata Ltd (RNTL)

Currency in BDT
416.30
-0.60(-0.14%)
Delayed Data·
Earnings results expected today
Unusual trading volume
RNTL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
415.80422.00
52 wk Range
372.00548.00
Key Statistics
Prev. Close
503.4
Open
419
Day's Range
415.8-422
52 wk Range
372-548
Volume
78.99K
Average Volume (3m)
34.64K
1-Year Change
-15.1966%
Book Value / Share
313.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RNTL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
615.05
Upside
+47.74%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 615.05
(+47.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 03, 2026
EPS / Forecast
7,11 / 5,64
Revenue / Forecast
10,93B / 10,7B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 22.11%
Dividend Yield
1.09%
Industry Median 4.03%
Annualised payout
5.50
Paid annually
5-Years Growth
-11.34%
Growth Streak

RNTL Income Statement

Compare RNTL to Peers and Sector

Metrics to compare
RNTL
Peers
Sector
Relationship
P/E Ratio
18.8x16.5x−0.5x
PEG Ratio
−1.32−0.970.00
Price/Book
1.3x1.6x2.6x
Price / LTM Sales
1.1x3.4x3.3x
Upside (Analyst Target)
47.7%32.2%47.7%
Fair Value Upside
Unlock0.4%6.6%Unlock

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pediatrics. In addition, it provides animal health products. The company was formerly known as Pfizer Laboratories (Bangladesh) Limited and changed its name to Renata Limited in 1993. Renata PLC was incorporated in 1972 and is headquartered in Dhaka, Bangladesh.

Employees
8366

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1,08M0,94%450,29M
Other Institutional Investors
93,80M81,78%39,05B
Public Companies & Retail Investors
19,81M17,27%8,25B
Total
114,7M100,00%47,75B

FAQ

What Is the Renata (RNTL) Stock Price Today?

The Renata stock price today is 416,30 BDT.

What Stock Exchange Does Renata Trade On?

Renata is listed and trades on the Dhaka Stock Exchange.

What Is the Stock Symbol for Renata?

The stock symbol for Renata is "RNTL."

Does Renata Pay Dividends? What’s The Current Dividend Yield?

The Renata dividend yield is 1.09%.

What Is the Renata Market Cap?

As of today, Renata market cap is 47,75B BDT.

What Is Renata's Earnings Per Share (TTM)?

The Renata EPS (TTM) is 22,11.

When Is the Next Renata Earnings Date?

Renata will release its next earnings report on May 04, 2026.

From a Technical Analysis Perspective, Is RNTL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Renata Stock Split?

Renata has split 21 times.

How Many Employees Does Renata Have?

Renata has 8366 employees.

What is the current trading status of Renata (RNTL)?

As of May 04, 2026, Renata (RNTL) is trading at a price of 416,30 BDT, with a previous close of 503,40 BDT. The stock has fluctuated within a day range of 415,80 BDT to 422,00 BDT, while its 52-week range spans from 372,00 BDT to 548,00 BDT.

What Is Renata (RNTL) Price Target According to Analysts?

The average 12-month price target for Renata is 615,05 BDT, with a high estimate of 677.1 BDT and a low estimate of 553 BDT. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +47,74% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.